Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer

M. Ben-David, J. L. Wittliff, M. Fekete, T. Kadar, S. Biran, Andrew V Schally

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The levels of prolactin receptors (PRL-R), based on a new micro-method, estrogen receptors (ER) and progesterone receptors (PG-R), were determined in 159 breast cancer specimens. Sixty-seven of 159 tumors (42%) had PRL-R levels of 20 fmol/mg protein or higher, and were regarded as PRL-R positive. In 60 of the 159 samples (38%), no PRL-R could be detected, and the remaining 32 samples (20%) were considered borderline. While a positive correlation was found between the presence of ER and PGR, no correlation was detected between PRL-R and any steroid receptors (r=-0.024 for ER vs PRL-R, 0.052 for PGR vs PRL-R and 0.002 for ER + PGR vs PRL-R). Furthermore, PRL-R in levels of 20 fmol/mg protein or higher were found in 35% of samples in which no steroid receptors were detected as well as in 38% and in 27% of samples which exhibited positive ER or PGR respectively (≥ 20 fmol/mg protein). On the other hand, in 47% of the samples possessing both ER and PGR, the PRL receptors could not be found. These results clearly demonstrate that in the human breast cancer, the presence of PRL-R is independent of the status of either ER or PGR. It is suggest that the measurement of PRL-R could serve as a chemical marker to guide a possible therapeutic use of PRL-suppressing drugs in women with breast cancer.

Original languageEnglish
Pages (from-to)327-334
Number of pages8
JournalBiomedicine and Pharmacotherapy
Volume42
Issue number5
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Prolactin Receptors
Steroid Receptors
Breast Neoplasms
Estrogen Receptors
Proteins
Therapeutic Uses
Progesterone Receptors

ASJC Scopus subject areas

  • Pharmacology

Cite this

Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer. / Ben-David, M.; Wittliff, J. L.; Fekete, M.; Kadar, T.; Biran, S.; Schally, Andrew V.

In: Biomedicine and Pharmacotherapy, Vol. 42, No. 5, 01.01.1988, p. 327-334.

Research output: Contribution to journalArticle

Ben-David, M. ; Wittliff, J. L. ; Fekete, M. ; Kadar, T. ; Biran, S. ; Schally, Andrew V. / Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer. In: Biomedicine and Pharmacotherapy. 1988 ; Vol. 42, No. 5. pp. 327-334.
@article{70c7f3994dd347a1a04f9823b9fc3649,
title = "Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer",
abstract = "The levels of prolactin receptors (PRL-R), based on a new micro-method, estrogen receptors (ER) and progesterone receptors (PG-R), were determined in 159 breast cancer specimens. Sixty-seven of 159 tumors (42{\%}) had PRL-R levels of 20 fmol/mg protein or higher, and were regarded as PRL-R positive. In 60 of the 159 samples (38{\%}), no PRL-R could be detected, and the remaining 32 samples (20{\%}) were considered borderline. While a positive correlation was found between the presence of ER and PGR, no correlation was detected between PRL-R and any steroid receptors (r=-0.024 for ER vs PRL-R, 0.052 for PGR vs PRL-R and 0.002 for ER + PGR vs PRL-R). Furthermore, PRL-R in levels of 20 fmol/mg protein or higher were found in 35{\%} of samples in which no steroid receptors were detected as well as in 38{\%} and in 27{\%} of samples which exhibited positive ER or PGR respectively (≥ 20 fmol/mg protein). On the other hand, in 47{\%} of the samples possessing both ER and PGR, the PRL receptors could not be found. These results clearly demonstrate that in the human breast cancer, the presence of PRL-R is independent of the status of either ER or PGR. It is suggest that the measurement of PRL-R could serve as a chemical marker to guide a possible therapeutic use of PRL-suppressing drugs in women with breast cancer.",
author = "M. Ben-David and Wittliff, {J. L.} and M. Fekete and T. Kadar and S. Biran and Schally, {Andrew V}",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "42",
pages = "327--334",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "5",

}

TY - JOUR

T1 - Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer

AU - Ben-David, M.

AU - Wittliff, J. L.

AU - Fekete, M.

AU - Kadar, T.

AU - Biran, S.

AU - Schally, Andrew V

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The levels of prolactin receptors (PRL-R), based on a new micro-method, estrogen receptors (ER) and progesterone receptors (PG-R), were determined in 159 breast cancer specimens. Sixty-seven of 159 tumors (42%) had PRL-R levels of 20 fmol/mg protein or higher, and were regarded as PRL-R positive. In 60 of the 159 samples (38%), no PRL-R could be detected, and the remaining 32 samples (20%) were considered borderline. While a positive correlation was found between the presence of ER and PGR, no correlation was detected between PRL-R and any steroid receptors (r=-0.024 for ER vs PRL-R, 0.052 for PGR vs PRL-R and 0.002 for ER + PGR vs PRL-R). Furthermore, PRL-R in levels of 20 fmol/mg protein or higher were found in 35% of samples in which no steroid receptors were detected as well as in 38% and in 27% of samples which exhibited positive ER or PGR respectively (≥ 20 fmol/mg protein). On the other hand, in 47% of the samples possessing both ER and PGR, the PRL receptors could not be found. These results clearly demonstrate that in the human breast cancer, the presence of PRL-R is independent of the status of either ER or PGR. It is suggest that the measurement of PRL-R could serve as a chemical marker to guide a possible therapeutic use of PRL-suppressing drugs in women with breast cancer.

AB - The levels of prolactin receptors (PRL-R), based on a new micro-method, estrogen receptors (ER) and progesterone receptors (PG-R), were determined in 159 breast cancer specimens. Sixty-seven of 159 tumors (42%) had PRL-R levels of 20 fmol/mg protein or higher, and were regarded as PRL-R positive. In 60 of the 159 samples (38%), no PRL-R could be detected, and the remaining 32 samples (20%) were considered borderline. While a positive correlation was found between the presence of ER and PGR, no correlation was detected between PRL-R and any steroid receptors (r=-0.024 for ER vs PRL-R, 0.052 for PGR vs PRL-R and 0.002 for ER + PGR vs PRL-R). Furthermore, PRL-R in levels of 20 fmol/mg protein or higher were found in 35% of samples in which no steroid receptors were detected as well as in 38% and in 27% of samples which exhibited positive ER or PGR respectively (≥ 20 fmol/mg protein). On the other hand, in 47% of the samples possessing both ER and PGR, the PRL receptors could not be found. These results clearly demonstrate that in the human breast cancer, the presence of PRL-R is independent of the status of either ER or PGR. It is suggest that the measurement of PRL-R could serve as a chemical marker to guide a possible therapeutic use of PRL-suppressing drugs in women with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023795290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023795290&partnerID=8YFLogxK

M3 - Article

C2 - 3191209

AN - SCOPUS:0023795290

VL - 42

SP - 327

EP - 334

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 5

ER -